CTI BIOPHARMA
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 2014-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.ctibiopharma.com/
Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 6
- Registration Number
- NCT02803762
- Locations
- π³π±
QPS Netherlands B.V., Groningen, Netherlands
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT02800889
- Locations
- πΊπΈ
Children's Hospital Los Angeles, Los Angeles, California, United States
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 28
- Registration Number
- NCT02765724
- Locations
- π©πͺ
APEX GmbH, Munich, Germany
π²π©Republican Clinical Hospital, Chisinau, Moldova, Republic of
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 311
- Registration Number
- NCT02055781
- Locations
- πΊπΈ
SCRI- Florida Cancer Specialists South Region, Fort Myers, Florida, United States
π¨π¦Saint John Regional Hospital, Saint John, New Brunswick, Canada
π¨π¦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 327
- Registration Number
- NCT01773187
- Locations
- πΊπΈ
CTI Investigational Site 10004, Omaha, Nebraska, United States
πΊπΈCTI Investigational Site 10002, Scottsdale, Arizona, United States
π¦πΊCTI Investigational Site 61006, Box Hill, Australia
Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 18
- Registration Number
- NCT01638442
- Locations
- πΊπΈ
Covance Clinical Research Unit Inc., Evansville, Indiana, United States
Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT01632436
- Locations
- πΊπΈ
UTHSCSA-Cancer Therapy-Research Center, San Antonio, Texas, United States
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 312
- Registration Number
- NCT01321541
- Locations
- πΊπΈ
Cancer Care Centers of South Texas-HOAST, San Antonio, Texas, United States
π¦πΉHospital Elisabethinen Linz, Internal Department 1 - Hemato-Oncology, Linz, Austria
πΈπ°National Cancer Institute, Department of Hematology and Transfusiology, Bratislava, Slovakia
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
- Conditions
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00577161
- Locations
- πΊπΈ
Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
πΊπΈVentura County Hematology Oncology Specialist, Oxnard, California, United States
πΊπΈCancer Care Center, Albany, New York, United States
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00576225
- Locations
- πΊπΈ
Memorial Cancer Institute, Hollywood, Florida, United States
πΊπΈLoyola University, Maywood, Illinois, United States
πΊπΈMary Crowley Medical Research Center, Dallas, Texas, United States